Overview

Rizatriptan 10 MG RPD in the Treatment of Acute Migraine

Status:
Completed

Trial end date:
2010-06-01

Target enrollment:

Participant gender:

Summary

This is a multicentre, open label, prospective, randomized, two-attack study with active comparator in patients reporting inadequate response to analgesics and/or triptans to examine the efficacy of Rizatriptan 10 mg RPD in this group of patients.

Phase:

Phase 4

Details

Lead Sponsor:

Universität Duisburg-Essen

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Rizatriptan